Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

6.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Risk factors on the unintentional injuries among rural children aged 0-12 in Shaanxi province].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2013
Same author

Adcyap1r1 genotype, posttraumatic stress disorder, and depression among women exposed to childhood maltreatment.

Depression and anxiety·2013
Same author

Current status and challenge of Human Parasitology teaching in China.

Pathogens and global health·2012
Same author

Molecular characterization of heterogeneous mesenchymal stem cells with single-cell transcriptomes.

Biotechnology advances·2012
Same author

Surgical treatment of ossification of the ligamentum flavum associated with dural ossification in the thoracic spine.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2012
Same author

Broadband focusing ultrasonic transducers based on dimpled LiNbO3 plate with inversion layer.

IEEE transactions on ultrasonics, ferroelectrics, and frequency control·2012
Same journal

PROTAC technology for prostate cancer treatment.

Acta materia medica·2025
Same journal

New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives.

Acta materia medica·2024
Same journal

Application of PROTACs in Target Identification and Target Validation.

Acta materia medica·2024
Same journal

Statistical Evaluation of Absolute Change versus Responder Analysis in Clinical Trials.

Acta materia medica·2023
Same journal

The 'New (Nu)-clear' evidence for the tumor-driving role of PI3K.

Acta materia medica·2023
Same journal

MDM2-BCL-X<sub>L</sub> PROTACs enable degradation of BCL-X<sub>L</sub> and stabilization of p53.

Acta materia medica·2023
See all related articles

Related Experiment Video

Updated: Jun 14, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

PROTACs Targeting Epigenetic Proteins.

Chao Zhang1, Yuna He2, Xiuyun Sun1

  • 1Changping Laboratory, Beijing 102206, China.

Acta Materia Medica
|September 2, 2024
PubMed
Summary
This summary is machine-generated.

Epigenetic protein degraders, like PROTACs, offer new ways to target disease-causing proteins, potentially overcoming drug resistance in epigenetic therapies.

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.5K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.3K

Related Experiment Videos

Last Updated: Jun 14, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.5K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.3K

Area of Science:

  • Molecular Biology
  • Genetics
  • Pharmacology

Background:

  • Epigenetics involves heritable gene function changes without altering DNA sequence.
  • Epigenetic regulation by writers, readers, and erasers is crucial for development and stability.
  • Epigenetic proteins are key targets in drug development, but resistance is a challenge.

Purpose of the Study:

  • To review novel degraders targeting epigenetic regulators (writers, readers, erasers).
  • To explore new applications of epigenetic protein degraders.
  • To address challenges and propose solutions in the PROTAC field for epigenetic targets.

Main Methods:

  • Literature review of recently developed epigenetic protein degraders.
  • Analysis of proteolysis-targeting chimeras (PROTACs) for epigenetic targets.
  • Discussion of challenges and future directions in the field.

Main Results:

  • Summary of diverse degraders targeting epigenetic writers, readers, and erasers.
  • Identification of emerging applications for these degraders.
  • Discussion of current limitations and potential advancements in PROTAC technology.

Conclusions:

  • Epigenetic protein degraders show promise in overcoming drug resistance.
  • PROTACs offer a strategy for targeting previously undruggable epigenetic proteins.
  • Continued innovation in PROTAC development is vital for epigenetic disease treatment.